免疫检查点抑制剂相关肌肉病症和长期随访患者的结果
相关实验视频
Updated: Jan 15, 2026

06:37
Immunolabelling Myofiber Degeneration in Muscle Biopsies
Published on: December 5, 2019
9.4K
Yahel Segal1, Georgios Mangioris1, Michel Toledano2,3
1Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Neurology(R) neuroimmunology & neuroinflammation
|October 6, 2025
概括
大多数患有免疫检查点抑制剂相关肌肉病的患者获得良好的功能结果,尽管残留症状很常见. 改善持续超过12个月,但男性性别和特定症状表明预后更差.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 免疫检查点抑制剂 (ICI) 是关键的癌症疗法.
- 与免疫相关的不良事件 (irAEs) 是常见的,肌肉病是常见的神经病的irAE.
- 与ICI相关的肌肉病的长期结果尚未得到充分证实.
研究的目的:
- 评估被诊断患有免疫检查点抑制剂相关肌肉病的患者的长期结果.
- 确定与ICI相关肌肉病变的疾病过程和预后相关的因素.
主要方法:
- 在梅奥诊所 (2013-2024) 的ICI相关肌肉病患者的回顾性审查.
- 与至少6个月的随访患者和在发病后2个月内死亡的患者之间的比较.
- 对临床表现,治疗和结果的分析.
主要成果:
- 87%的患者在最后一次随访时取得了良好的结果 (irAE等级≤2),48%的患者有残留症状.
- 大多数患者表现出逐渐改善,即使在停止治疗后.
- 男性的性别,柱状和轴向参与与更差的预后有关.
结论:
- 与ICI相关的肌肉病的长期功能结果通常是有利的,但残留症状在约一半的患者中持续存在.
- 症状的改善可以持续超过12个月.
- 识别特定的临床特征可以预测更严重的疾病过程,暗示耐火病例中的非典型病理.
相关概念视频
Myocarditis IV: Nursing Management
205
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
205
Myasthenia Gravis: Diagnostic Tests
1.9K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.9K
Myasthenia Gravis: Overview and Treatment
2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K
Myocarditis III: Medical Management
174
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
174
Myocarditis II: Clinical Features and Diagnostic Tests
265
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
265

